Clinical trial
Phase 3 Study of Dexpramipexole in ALS
NCT01281189
Study timeline
Study start (unknown)2011-03-01Date precision: month
Registry last updated2021-06-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Amyotrophic Lateral Sclerosisunresolved
Interventions
DexpramipexoleDRUG
PlaceboDRUG
Sponsors & collaborators
Knopp Bioscienceslead sponsor
Mapped research locations
PhiladelphiaPennsylvania, United States2MadridSpain2BarcelonaSpain2MontrealQuebec, Canada2New YorkNew York, United States1HoustonTexas, United States1ChicagoIllinois, United States1DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1MiamiFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01281189 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.